Century Therapeutics Inc
NASDAQ:IPSC

Watchlist Manager
Century Therapeutics Inc Logo
Century Therapeutics Inc
NASDAQ:IPSC
Watchlist
Price: 2.15 USD 5.39%
Market Cap: 187.7m USD

Net Margin
Century Therapeutics Inc

-23.4%
Current
-3 415%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-23.4%
=
Net Income
-26.5m
/
Revenue
113.3m

Net Margin Across Competitors

No Stocks Found

Century Therapeutics Inc
Glance View

Market Cap
186m USD
Industry
Biotechnology

Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. The company is headquartered in Philadelphia, Pennsylvania and currently employs 170 full-time employees. The company went IPO on 2021-06-17. The firm is focused on developing transformative allogeneic, pluripotent stem cells (iPSC)-derived natural killer (NK) and T cell therapies to create products for the treatment of both solid tumor and hematological malignancies. Its Allo-Evasion technology is intended to prevent rejection of cell products by the host immune system, and manufacturing capabilities intended to minimize product development and supply risk. The firm's pipeline includes CNTY-101, CNTY-103, CNTY-102 and CNTY-104. The Company’s lead product candidate, CNTY-101, is focused on targeting B-cell lymphoma. CNTY-103 is designed to treat glioblastoma. CNTY-102 is designed to improve B-cell malignancy treatment. CNTY-104, is being developed to treat acute myeloid leukemia (AML). CAR design is a component of cell therapy product candidates. In addition to its programs, the Company is also actively engaged in a number of earlier stage discovery programs.

IPSC Intrinsic Value
4.58 USD
Undervaluation 53%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-23.4%
=
Net Income
-26.5m
/
Revenue
113.3m
What is the Net Margin of Century Therapeutics Inc?

Based on Century Therapeutics Inc's most recent financial statements, the company has Net Margin of -23.4%.

Back to Top